ScholarIQanswers from OpenAlex & ORCID
Maya H Buch
ResearcherPublications, citations & collaboration network
Maya H Buch is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Maya H Buch have?
ScholarIQindexed works
Maya H Buch has 464 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Maya H Buch have?
ScholarIQcitation count
Maya H Buch has 26,683 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Maya H Buch?
ScholarIQh-index
Maya H Buch has an h-index of 69 in OpenAlex.
What is the i10-index of Maya H Buch?
ScholarIQi10-index
Maya H Buch has an i10-index of 181 in OpenAlex.
What is the ORCID of Maya H Buch?
ScholarIQorcid
The ORCID for Maya H Buch is on the source record.
What is the OpenAlex record for Maya H Buch?
ScholarIQopenalex
The OpenAlex for Maya H Buch is on the source record.
What are the most-cited papers on Maya H Buch?
ScholarIQmost cited works
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, Alexandre Sepriano, Ronald van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, Johan Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Myrna Cardiel, Diederik De Cock, Cătălin Codreanu, Maurizio Cutolo, Christopher J Edwards, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques‐Eric Gottenberg, Merete Lund Hetland, T. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller‐Ladner, Eduardo Mysler, José António Pereira da Silva, Gyula Poór, Janet Pope, Andrea Rubbert‐Roth, Adeline Ruyssen‐Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S Smolen, Robert Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher J Edwards, Kimme L Hyrich, Janet Pope, Savia de Souza, Tanja Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Myrna Cardiel, Katerina Chatzidionysiou, Cătălin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques‐Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo Mysler, Peter Nash, Gyula Poór, Gorica Ristić, Felice Rivellese, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Nikolay Stoilov, Anja Strangfeld, Annette H M van der Helm–van Mil, Elsa van Duuren, T. P. M. Vliet Vlieland, René Westhovens, Désirée van der Heijde
\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld, Maxime Dougados, Paul Emery, C. Gaujoux-Viala, Simone Gorter, Rachel Knevel, J. Nam, Monika Schoels, Daniel Aletaha, Maya H Buch, Laure Gossec, T. Huizinga, J. W. J. Bijlsma, Gerd R Burmester, Bernard Combe, Maurizio Cutolo, Cem Gabay, Juan J. Gómez‐Reino, Marios Kouloumas, Tore K Kvien, E. Martín‐Mola, Iain B. McInnes, Karel Pavelká, Piet L. C. M. van Riel, M. Scholte, David L. Scott, Tuulikki Sokka, Guido Valesini, Ronald van Vollenhoven, Kevin Winthrop, John B. Wong, A. Zink, Désirée van der Heijde
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Frances Humby, Patrick Durez, Maya H Buch, Myles Lewis, Hasan Rizvi, Felice Rivellese, Alessandra Nerviani, Giovanni Giorli, Arti Mahto, Carlomaurizio Montecucco, Bernard Lauwerys, Nora Ng, Pauline Ho, Michele Bombardieri, Vasco C. Romão, Patrick Verschueren, Stephen Kelly, Pier Paolo Sainaghi, Nagui Gendi, Bhaskar Dasgupta, Alberto Cauli, Piero Reynolds, Juan D. Cañete, Robert J. Moots, Peter C. Taylor, Christopher J Edwards, John D. Isaacs, Peter Sasieni, Ernest Choy, Costantino Pitzalis, Charlotte Thompson, Serena Bugatti, Mattia Bellan, Mattia Congia, Christopher Holroyd, Arthur G. Pratt, João Eurico Fonseca, Laura White, Louise Warren, Joanna Peel, Rebecca Hands, Liliane Fossati‐Jimack, Gaye Hadfield, Georgina Thorborn, Julio Ramírez, Raquel Celis
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
Andrew P. Cope, Marianna Jasenecova, Joana C. Vasconcelos, Andrew Filer, Karim Raza, Sumera Qureshi, Maria Antonietta D’Agostino, Iain B. McInnes, John D. Isaacs, Arthur G. Pratt, Benjamin A. Fisher, Christopher D. Buckley, Paul Emery, Pauline Ho, Maya H Buch, Coziana Ciurtin, Dirkjan van Schaardenburg, Thomas Huizinga, René E. M. Toes, Evangelos Georgiou, Joanna Kelly, Caroline Murphy, A Toby Prevost, Sam Norton, Heidi Lempp, Maria Opena, Sujith Subesinghe, Toby Garrood, Bina Menon, Nora Ng, Karen M. Douglas, Christos Koutsianas, Faye A. H. Cooles, Marie Falahee, Irene Echavez-Naguicnic, Anurag Bharadwaj, Michael Villaruel, Ira Pande, David Collins, Suzannah Pegler, Sabrina Raizada, Stefan Siebert, G. Fragoulis, Jesusa Guinto, James Galloway, Andrew I Rutherford, Theresa Barnes, Helen Jeffrey, Yusuf Patel, Michael Batley, Brendan O'Reilly, Srivinisan Venkatachalam, Thomas Sheeran, Claire Gorman, Piero Reynolds, Asad Khan, Nicola Gullick, Siwalik Banerjee, Kulveer Mankia, Deepak Jordan, Jane Rowlands, Mirian Starmans‐Kool, James C. Taylor, Pradip Nandi, Ilfita Sahbudin, Mark Maybury, Samantha Hider, Ann Barcroft, Jeremy McNally, Jo Kitchen, Muhammad Nisar, Vanessa Quick